Oncotarget

Oncotarget

LATEST COMMUNITY NEWS & EVENTS BY ONCOTARGET:

  • Behind the Study: EMT, Endothelial Cells & Tumor Growth
    Dr. Tapasree Roy Sarkar describes a research paper she co-authored, entitled, “Carcinoma cells that have undergone an epithelial-mesenchymal transition differentiate into endothelial cells and contribute to tumor growth.”
  • Oncotarget Testimonial: Dr. Tapasree Roy Sarkar
    Dr. Tapasree Roy Sarkar from the Department of Biology at Texas A&M University discusses her experience publishing the paper, “Carcinoma cells that have undergone an epithelial-mesenchymal transition differentiate into endothelial cells and contribute to tumor growth,” with Oncotarget.
  • Behind the Study: Oral Squamous Carcinoma Cell Migration and Viability
    Dr. Gary S. Goldberg from Rowan University details a study he co-authored, published by Oncotarget in 2015, and entitled, “Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.”

View All Posts >>

ABOUT ONCOTARGET.NET:

Read about community news and events sponsored by Oncotarget – a bi-weekly peer-reviewed open access scientific journal focusing on all topics surrounding cancer research. Visit Oncotarget.org for the latest articles about new and trending peer-reviewed scientific papers published by Oncotarget, part of the Impact Journals family of scientific publications.

ABOUT ONCOTARGET:

Oncotarget is published by Impact Journals of Orchard Park, New York. Impact Journals meets the standards established Wellcome Trust Publisher Requirements and is included on the Wellcome Trust List of Compliant Publishers.

Oncotarget is proud to have multiple Nobel Prize winning members on its editorial board, in addition to editors who have won the Lasker Prize and other prestigious recognitions. The open-access model employed by Oncotarget allows for free dissemination of thoroughly vetted peer-reviewed research material to the general public, leading to bigger and more frequent scientific breakthroughs. Because of Oncotarget’s uniquely varied scope, the journal has consistently published research on a wide range of subject areas, allowing readers to access an unparalleled diversity of knowledge in only one publication.

The founding editors of Oncotarget are Mikhail (Misha) Blagosklonny and Andrei Gudkov. Dr. Blagosklonny is well-known for his research in the field of aging, having published numerous papers on the subject. Mikhail is credited for advancing groundbreaking research of the drug Rapamycin, an anti-aging medicine that has shown to slow down the aging process. Having been featured in numerous publications on aging including a Scientific American article titled “A New Path to Longevity,” Mikhail continues to provide meaningfully important contributions to the scientific community.

CONTACT INFORMATION:

Dr. Blagosklonny can be followed on Twitter @Blagosklonny and you can visit his website here.

To get in touch with Oncotarget, please visit our website. The journal’s ISSN is 1949-2553 and is indexed and/or archived in PubMed, Scopus, PMC, and the Chan Zuckerberg Meta initiative.